株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

角膜炎:パイプライン分析

Keratitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200462
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
角膜炎:パイプライン分析 Keratitis - Pipeline Review, H2 2016
出版日: 2016年10月29日 ページ情報: 英文 70 Pages
概要

角膜炎とは角膜の炎症です。症状としては、眼の充血、眼痛、視覚低下(かすみ目)、視力低下、光に対する過敏症などが現れます。 危険因子として、ウィルス感染、けが、気候条件、免疫力の低下などが挙げられます。

当レポートでは、角膜炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

角膜炎 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Adamis Pharmaceuticals Corporation
  • Cellceutix Corporation
  • Dompe Farmaceutici S.p.A.
  • Kala Pharmaceuticals, Inc.
  • Peregrine Pharmaceuticals, Inc.
  • RegeneRx Biopharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • The Medicines Company

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • brilacidin
  • C-31G
  • IBN-1
  • loteprednol etabonate
  • moxifloxacin hydrochloride
  • PGN-632
  • PIM-45
  • Recombinant Human Nerve Growth Factor
  • RGN-259
  • Small Molecules to Inhibit ATM for Herpes Keratitis
  • STP-601
  • targocil
  • tigecycline

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8596IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2016, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively for Keratitis.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratitis Overview
  • Therapeutics Development
    • Pipeline Products for Keratitis - Overview
    • Pipeline Products for Keratitis - Comparative Analysis
  • Keratitis - Therapeutics under Development by Companies
  • Keratitis - Therapeutics under Investigation by Universities/Institutes
  • Keratitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Keratitis - Products under Development by Companies
  • Keratitis - Products under Investigation by Universities/Institutes
  • Keratitis - Companies Involved in Therapeutics Development
    • Adamis Pharmaceuticals Corporation
    • Dompe Farmaceutici S.p.A.
    • NanoViricides, Inc.
    • ReceptoPharm, Inc.
    • RegeneRx Biopharmaceuticals, Inc.
    • SIFI S.p.A
    • The Medicines Company
  • Keratitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acyclovir sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-2088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-31G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dipyridamole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Herpecide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDE-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PIM-45 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polihexanide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-259 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPI-MN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Neurotrophic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • targocil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tigecycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Keratitis - Dormant Projects
  • Keratitis - Discontinued Products
  • Keratitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
      • May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease
      • Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
      • Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
      • Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
      • Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
      • Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
      • Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
      • Sep 25, 2014: EuCornea: Dompe wins the "Best Poster Award" for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis
      • Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
      • Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Keratitis, H2 2016
  • Number of Products under Development for Keratitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
  • Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Keratitis - Pipeline by NanoViricides, Inc., H2 2016
  • Keratitis - Pipeline by ReceptoPharm, Inc., H2 2016
  • Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
  • Keratitis - Pipeline by SIFI S.p.A, H2 2016
  • Keratitis - Pipeline by The Medicines Company, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Keratitis - Dormant Projects, H2 2016
  • Keratitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Keratitis, H2 2016
  • Number of Products under Development for Keratitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top